References
- Bauer, P., Kohne, K. (1994). Evaluation of experiments with adaptive interim analyses. Biometrics 50:2079–2090.
- Cui, L., Hung, H., Wang, S.-J. (1999). Modification of sample size in group sequential clinical trials. Biometrics 55:853–857.
- Hsiao, C. F., Xu, J. Z., Liu, J. P. (2003). A group sequential approach to evaluation of bridging studies. Journal of Biopharmaceutical Statistics 13:793–801.
- Hsiao, C. F., Xu, J. Z., Liu, J. P. (2005). A two-stage design for bridging studies. Journal of Biopharmaceutical Statistics 15:75–83.
- Huang, Q., Chen, G., Yuan, Z., Lan, K. K. G. (2012). Design and sample size consideration for Simultaneous Global Drug Development Program. Journal of Biopharmaceutical Statistics 22:1060–1073.
- ICH (International Conference on Harmonization) Tripartite Guidance E5. (1998). Ethnic factor in the acceptability of foreign data. The US Federal Register 83:31790–31796.
- Lan, K. K. G., Soo, Y., Siu, C., Wang, M. (2005). The use of weighted Z-tests in medical research. Journal of Biopharmaceutical Statistics 15:625–639.
- Liu, K., Yuan, Z., Chen, G., Huang, Q., Wenrich, J. (2015). Statistical properties of the design for Simultaneous Global Drug Development Program. Journal of Biopharmaceutical Statistics 25:1135–1144.
- Liu, Q., Chi, G. (2001). On sample size and inference for two-stage adaptive designs. Biometrics 57:172–177.
- Ministry of Health, Labour and Welfare. (2007). Basic Principles on Global Clinical Trials. Tokyo, Japan.
- Proschan, M. A., Hunsberger, S. A. (1995). Designed extension of studies based on conditional power. Biometrics 51:1315–1324.